BMA
ABBV icon

Brooks Moore & Associates’s AbbVie ABBV Stock Holding History

Brooks Moore & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.96M Sell
27,417
-1,050
-4% -$233K 2.99% 10
2025
Q4 		$6.5M Buy
28,467
+175
+0.6% +$39.9K 3.2% 7
2025
Q3 		$6.55M Sell
28,292
-200
-0.7% -$40.7K 3.32% 4
2025
Q2 		$5.39M Buy
28,492
+149
+0.5% +$27.7K 2.91% 6
2025
Q1 		$5.94M Sell
28,343
-200
-0.7% -$38.9K 3.35% 4
2024
Q4 		$5.07M Hold
28,543
– – 3% 7
2024
Q3 		$5.64M Sell
28,543
-153
-0.5% -$28.6K 3.33% 5
2024
Q2 		$4.92M Hold
28,696
– – 3.17% 9
2024
Q1 		$5.23M Sell
28,696
-85
-0.3% -$14.6K 3.35% 7
2023
Q4 		$4.46M Sell
28,781
-200
-0.7% -$29.2K 3.07% 9
2023
Q3 		$4.32M Sell
28,981
-1,349
-4% -$198K 3.26% 7
2023
Q2 		$4.09M Sell
30,330
-488
-2% -$71.6K 2.88% 10
2023
Q1 		$4.91M Buy
30,818
+585
+2% +$89.4K 3.53% 5
2022
Q4 		$4.89M Sell
30,233
-6,713
-18% -$1.03M 3.57% 7
2022
Q3 		$4.96M Buy
36,946
+892
+2% +$128K 4.01% 3
2022
Q2 		$5.52M Sell
36,054
-1,534
-4% -$234K 3.98% 2
2022
Q1 		$6.09M Sell
37,588
-2,800
-7% -$407K 3.74% 2
2021
Q4 		$5.47M Buy
40,388
+1,060
+3% +$125K 3.21% 3
2021
Q3 		$4.24M Sell
39,328
-4,645
-11% -$531K 2.78% 5
2021
Q2 		$4.95M Sell
43,973
-375
-0.8% -$42.2K 3.16% 3
2021
Q1 		$4.8M Buy
44,348
+2,375
+6% +$254K 3.25% 4
2020
Q4 		$4.5M Buy
41,973
+2,066
+5% +$199K 3.48% 4
2020
Q3 		$3.5M Buy
39,907
+6,719
+20% +$633K 3.01% 5
2020
Q2 		$3.26M Buy
33,188
+2,371
+8% +$209K 3.05% 5
2020
Q1 		$2.35M Buy
30,817
+2,110
+7% +$180K 2.49% 9
2019
Q4 		$2.54M Buy
28,707
+1
+0% +$83 2.02% 15
2019
Q3 		$2.17M Buy
28,706
+7,924
+38% +$543K 1.84% 19
2019
Q2 		$1.51M Buy
20,782
+3,175
+18% +$250K 1.3% 29
2019
Q1 		$1.42M Buy
17,607
+1,200
+7% +$98.2K 1.29% 31
2018
Q4 		$1.51M Buy
+16,407
New +$1.44M 1.52% 24

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brooks Moore & Associates's ABBV Position: Q1 2026 in Review

Brooks Moore & Associates reduced its AbbVie (ABBV) stake by 3.7% in Q1 2026, selling an estimated $233K and leaving 27,417 shares worth $5.96M. The position accounts for 2.99% of the portfolio, ranked #10.

Brooks Moore & Associates first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $6.55M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Brooks Moore & Associates held 27,417 shares of AbbVie worth $5.96M as of Q1 2026.
  • Brooks Moore & Associates sold 1,050 AbbVie shares in Q1 2026, an estimated $233K.
  • AbbVie made up 2.99% of Brooks Moore & Associates's portfolio in Q1 2026, its #10 holding.
  • Brooks Moore & Associates first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Brooks Moore & Associates's AbbVie position peaked at $6.55M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Brooks Moore & Associates's 13F filing for Q1 2026, filed 15 May 2026.